IRBy Calypso Research8 min read

Ingersoll Rand (IR) Q4 2025 Earnings Analysis

Ingersoll Rand’s Profit Winds Blow Up 10.1% to $2.1B

Key Takeaways

Ingersoll Rand (IR) reported Q4 2025 earnings with revenue of $2.1B, representing a +10.1% year-over-year change. The stock moved +4.8% on earnings day.

The bull case: A resilient aftermarket- and recurring-revenue-heavy portfolio, disciplined high-return M&A (especially in life sciences), and conservative guidance on volumes, margins, and cash set Ingersoll Rand up to consistently beat expectations and compound EPS and FCF through the cycle.

The bear case: Persistent tariff and investment headwinds, tougher life sciences comps, region-specific macro risks in China and Europe, and reliance on ongoing M&A to drive growth could cap margin expansion, pressure free cash flow conversion, and expose the stock if growth or deal returns disappoint.

Financial Highlights

  • Revenue: $2.1B (+10.1% YoY)
  • Gross Profit: $503M (24.1% margin, -18.9% YoY)
  • Operating Income: $664M (31.7% margin, +11.8% YoY)
  • Net Income: $266M
  • TTM Revenue: $7.7B

Stock Performance

  • Earnings Day Move: +4.8%
  • Year-to-Date: +17.8%
  • 1-Year Return: +13.3%
  • vs. S&P 500 (since earnings): +31.3%
  • vs. Nasdaq (since earnings): +34.0%

View live IR data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Ingersoll Rand's Q4 2025 earnings call:

How Conservative Is 2026 Organic Growth & Volume Guidance vs. Improving Short‑Cycle Indicators?

Sentiment: Positive

"We are not embedding any market recovery here, and very stable sequentially here from what we are seeing today. So that is what we are embedding in the guidance." — Vicente Reynal
"We do expect volume performance to improve as we think about the second half versus the first half... probably closer to probably somewhere in the flattish realm as we get to the back half of the year... but we have not baked any, what I will call, meaningful recovery per se in." — Vikram U. Kini

Margin Durability in the Face of Tariffs, Price/Cost Dynamics, and Growth Investments

Sentiment: Positive

"We did expect some headwinds on the margin front, particularly in the first half of the year, particularly as we lap kind of some of the annualizing of the tariffs... however, we do expect to be price/cost neutral in the first half and then we expect to see that margin expansion take hold in the second half." — Vikram U. Kini
"Our expectation for ITS margins is that on a total-year basis, we do expect to be relatively flattish year over year... driven by the carryover of the tariffs... as well as the continued targeted commercial investment for growth... PST we do expect to be up, you know, triple-digit margin expansion." — Vikram U. Kini

Sustainability and Quality of Life Sciences Growth (Including ILC Dover & Synomics)

Sentiment: Positive

"Life sciences is progressing and improving sequentially... pharma and biopharma production, we continue to see very good funnel and booking activity both in the U.S. and outside the U.S.... in the lab, analytical diagnostic equipment market, very good pipeline activity, given some of the U.S. reshoring of drug discovery and development and the need for automation." — Vicente Reynal
"We continue to be really encouraged... the bolt-on M&A kind of playbook is really taking root as well in our life sciences portfolio... the Synomics acquisition... is a very attractive kind of nice additive complementary bolt-on... clearly the comps are there, but we are still encouraged by the momentum we are seeing, which you saw in the Q4 order rate." — Vikram U. Kini

M&A Strategy, Valuations, and the Risk/Reward of a Larger Deal

Sentiment: Positive

"The opportunity in the funnel remains really strong... currently have nine companies under LOI... I will characterize the pipeline still as being bolt-on in nature. But there is definitely a couple that we have been cultivating for quite some time that could be on the larger purchase price or maybe a $1,000,000,000 or so." — Vicente Reynal
"We continue to actually, as you have seen, do really well with the presynergy multiple. In 2025, we average roughly 9.2 times, to be exact, the presynergy multiple... our M&A flywheel is differentiated... a lot of these transactions are sole source... family-owned companies... we have a bit of an advantage... to have a very good price multiple." — Vicente Reynal

Recurring Revenue Ramp: Profit Accretion vs. Reinvestment Drag

Sentiment: Positive

"Not only the $450,000,000 of revenue... but the fact that we now have approximately $1.1 billion in future revenue from existing contracts... that gives us good confidence here as we can continue the ramp... we always said that will not be linear and will require continued ramp to achieve our long-term investor day target." — Vicente Reynal
"The recurring revenue business... is, across the entire enterprise, typically a higher margin profile... margins can play in that range that you are speaking to... but we are also making sure that we are taking that opportunity to reinvest appropriately in the business... a lot of our commercial reinvestments are in areas like service technicians... to make sure that we can continue to grow our recurring revenue base." — Vikram U. Kini

Bull Case

A resilient aftermarket- and recurring-revenue-heavy portfolio, disciplined high-return M&A (especially in life sciences), and conservative guidance on volumes, margins, and cash set Ingersoll Rand up to consistently beat expectations and compound EPS and FCF through the cycle.

Bear Case

Persistent tariff and investment headwinds, tougher life sciences comps, region-specific macro risks in China and Europe, and reliance on ongoing M&A to drive growth could cap margin expansion, pressure free cash flow conversion, and expose the stock if growth or deal returns disappoint.

Looking Ahead

With revenue growing +10.1% year-over-year, the key question is whether Ingersoll Rand can sustain this growth trajectory, particularly around how Conservative Is 2026 Organic Growth & Volume Guidance vs. Improving Short‑Cycle Indicators?. With operating margins at 31.7%, margin trends will remain a focal point. The market's positive reaction on earnings day suggests confidence in management's direction, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Ingersoll Rand's revenue in Q4 2025?

Ingersoll Rand reported Q4 2025 revenue of $2.1B, representing a +10.1% year-over-year change.

Did Ingersoll Rand beat earnings expectations in Q4 2025?

The stock rose +4.8% on earnings day, suggesting the results met or exceeded market expectations. The current bull case centers on: A resilient aftermarket- and recurring-revenue-heavy portfolio, disciplined high-return M&A (especially in life sciences), and conservative guidance on volumes, margins, and cash set Ingersoll Rand up to consistently beat expectations and compound EPS and FCF through the cycle.

What is the bull case for IR stock?

The bull case for IR centers on: A resilient aftermarket- and recurring-revenue-heavy portfolio, disciplined high-return M&A (especially in life sciences), and conservative guidance on volumes, margins, and cash set Ingersoll Rand up to consistently beat expectations and compound EPS and FCF through the cycle.

What is the bear case for IR stock?

The bear case for IR centers on: Persistent tariff and investment headwinds, tougher life sciences comps, region-specific macro risks in China and Europe, and reliance on ongoing M&A to drive growth could cap margin expansion, pressure free cash flow conversion, and expose the stock if growth or deal returns disappoint.

How has IR stock performed since its Q4 2025 earnings?

IR moved +4.8% on the day of its Q4 2025 earnings report, outperforming the S&P 500 by +31.3% since earnings. Year-to-date, the stock has returned +17.8%.

Browse all 400+ earnings reports →

Learn More

Analyze IR in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Ingersoll Rand and 400+ other stocks, explore the full platform.

Open IR on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.